Endocrine News and Research

RSS

MBSR reduces fasting glucose, improves quality of life in overweight and obese women

A treatment known as mindfulness-based stress reduction (MBSR) may decrease fasting glucose and improve quality of life in overweight and obese women, new research suggests.

9 Mar 2015

Gastrointestinal colonization with methanogens increases difficulty of losing weight after bariatric surgery

A new study finds that after weight loss surgery, people whose breath has high concentrations of both hydrogen and methane gases have a lower percentage weight loss than other bariatric surgery patients do. The study results will be presented Thursday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

Phase 3 trial results show that new testosterone nasal gel is effective and practical

A new testosterone nasal gel raises men's low testosterone levels to normal, with few side effects, according to the results of a phase 3 clinical trial to be presented Saturday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center study will be presented Sunday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

$Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures$

Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures

Abaloparatide-SC, an injectable drug being studied for the treatment of postmenopausal osteoporosis, reduces the rate of new spinal fractures by a statistically significant 86 percent and as well as statistically significant reductions in the fracture rate at other parts of the body, a phase 3 clinical trial finds. Results of the ACTIVE fracture prevention trial will be described in a late-breaking oral presentation Thursday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

Liraglutide may help obese adults achieve weight loss

Obesity guidelines recommend an initial weight loss goal of 5 to 10% of start weight to improve health. A recent study found that patients who received liraglutide 3.0 mg, combined with fewer calories and more physical activity, were more than twice as likely to achieve at least that level of weight loss, compared to patients on placebo who made similar lifestyle changes.

7 Mar 2015

Genetically modified soybean oil has fewer negative metabolic consequences than regular soybean oil

A new soybean oil genetically modified to be healthier than conventional soybean oil causes obesity, pre-diabetes and fatty liver in a nearly identical manner to that of regular soybean oil when part of a typical American high-fat diet, an animal study shows.

6 Mar 2015

Exposure to endocrine-disrupting chemicals estimated to cost EU €157 billion a year

A new economic analysis found exposure to endocrine-disrupting chemicals likely costs the European Union €157 billion ($209 billion) a year in actual health care expenses and lost earning potential, according to a new series of studies published in the Endocrine Society's Journal of Clinical Endocrinology and Metabolism.

6 Mar 2015

Oxytocin nasal spray helps healthy men reduce consumption of fatty foods

A synthetic nasal formulation of the hormone oxytocin reduced caloric intake in healthy men, particularly consumption of fatty foods, after a single treatment, a new study finds. The results, to be presented Sunday at The Endocrine Society's 97th annual meeting in San Diego, confirm those of animal studies showing oxytocin reduces food intake.

6 Mar 2015

GM soybean oil as unhealthy as regular soybean oil, but may not cause insulin resistance

Soybean oil accounts for more than 90 percent of all the seed oil production in the United States. Genetically modified (GM) soybean oil, made from seeds of GM soybean plants, was recently introduced into the food supply on the premise that it is healthier than conventional soybean oil.

6 Mar 2015

Phthalate exposure in pregnancy adversely affects masculinization of male genitals in babies

Exposure to hormone-altering chemicals called phthalates - which are found in many plastics, foods and personal care products - early in pregnancy is associated with a disruption in an essential pregnancy hormone and adversely affects the masculinization of male genitals in the baby, according to research led by the University of Pittsburgh Graduate School of Public Health.

6 Mar 2015

Gut bacteria may help predict risk for diabetes

The composition of intestinal bacteria and other micro-organisms--called the gut microbiota--changes over time in unhealthy ways in black men who are prediabetic, a new study finds. The results will be presented Friday at the Endocrine Society's 97th annual meeting in San Diego.

5 Mar 2015

New study shows association between BPA exposure and ASD in children

A newly published study is the first to report an association between bisphenol-A (BPA), a common plasticizer used in a variety of consumer food and beverage containers, with autism spectrum disorder (ASD) in children.

3 Mar 2015

Alizé Pharma announces launch of AZP-531 Phase II trial in patients with Prader-Willi syndrome

Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today announces the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome.

3 Mar 2015

Novel financing technique may unlock funding for developing 'orphan' drugs to treat rare diseases

A paper published today, "Financing translation: Analysis of the NCATS rare-diseases portfolio" in Science Translational Medicine, demonstrates the potential of a new financing technique to reduce the risk associated with investing in the treatment of new diseases and potentially unlock new levels of funding for developing so-called "orphan" drugs.

28 Feb 2015

Chiasma closes $70 million Series E financing round

Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E financing round.

27 Feb 2015

Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments.

21 Feb 2015

20th annual edition of NCCN Guidelines for Breast Cancer published

Breast cancer is the most frequently diagnosed cancer globally and the leading cause of cancer-related death in women. However, the incidence of breast cancer has somewhat stabilized over the past few decades, and breast cancer mortality appears to be declining, suggesting a benefit from the combination of early detection and more effective treatment.

16 Feb 2015

Congressional briefing to focus on importance of including female subjects in medical research

The Endocrine Society and Society for Women's Health Research are co-sponsoring a Congressional briefing on February 17 that will focus on the importance of including female subjects in both preclinical and clinical biomedical research, which could potentially revolutionize medical research and scientific discovery.

16 Feb 2015

Adult survivors of childhood cancer at risk for pituitary hormone deficiencies

Decades after undergoing cranial irradiation for childhood cancer, St. Jude Children's Research Hospital investigators found that adult survivors of pediatric cancer remain at risk for pituitary hormone deficiencies that may diminish their health and quality of life.

16 Feb 2015

Endocrine News and Research

MBSR reduces fasting glucose, improves quality of life in overweight and obese women

Gastrointestinal colonization with methanogens increases difficulty of losing weight after bariatric surgery

Phase 3 trial results show that new testosterone nasal gel is effective and practical

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures

Liraglutide may help obese adults achieve weight loss

Genetically modified soybean oil has fewer negative metabolic consequences than regular soybean oil

Exposure to endocrine-disrupting chemicals estimated to cost EU €157 billion a year

Oxytocin nasal spray helps healthy men reduce consumption of fatty foods

GM soybean oil as unhealthy as regular soybean oil, but may not cause insulin resistance

Phthalate exposure in pregnancy adversely affects masculinization of male genitals in babies

Gut bacteria may help predict risk for diabetes

New study shows association between BPA exposure and ASD in children

Alizé Pharma announces launch of AZP-531 Phase II trial in patients with Prader-Willi syndrome

Novel financing technique may unlock funding for developing 'orphan' drugs to treat rare diseases

Chiasma closes $70 million Series E financing round

Palbociclib extends progression-free survival in advanced breast cancer patients

20th annual edition of NCCN Guidelines for Breast Cancer published

Congressional briefing to focus on importance of including female subjects in medical research

Adult survivors of childhood cancer at risk for pituitary hormone deficiencies

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News